JACS:研究发现可诊断良性胰腺囊肿标记物

2014-02-19 cmt wl

来自印第安纳大学医学院的研究人员近日发现了一种可以用于诊断胰腺良性囊肿的准确性较高的无创检查方法。该技术通过对胰腺囊肿囊液进行分析,可以明确有恶变倾向的胰腺良性囊肿的常见类型。相关研究于2013年12月24日在线发表在 J Am Coll Surg 杂志上。 新型的生物标记物为胰腺囊肿囊液中同种异型血管内皮生长因子A(VEGF-A),在临床中对接受内镜检查的胰腺囊肿患者会常规行胰液检查。研究人员

来自印第安纳大学医学院的研究人员近日发现了一种可以用于诊断胰腺良性囊肿的准确性较高的无创检查方法。该技术通过对胰腺囊肿囊液进行分析,可以明确有恶变倾向的胰腺良性囊肿的常见类型。相关研究于2013年12月24日在线发表在 J Am Coll Surg 杂志上。

新型的生物标记物为胰腺囊肿囊液中同种异型血管内皮生长因子A(VEGF-A),在临床中对接受内镜检查的胰腺囊肿患者会常规行胰液检查。研究人员在对87名患者的临床资料进行分析后发现,高水平VEGF-A确诊胰腺良性囊肿的准确性可高达99%。

这种新型囊液蛋白生物标记物,无需手术仅通过检测其水平高低就能将浆液性囊性肿瘤这种良性囊性病变与其他癌性或癌前性囊性病变加以鉴别诊断。

从某种程度上说,胰腺癌是最为凶险的癌症之一,因为确诊时通常已到晚期并且治疗手段相对受限。根据美国国家癌症研究所(NCI)公布的数据显示,今年被诊断胰腺癌的人数将达45,220人,其中约有38,460人将死于该病。

胰腺癌的治疗手段包括化疗、放疗和外科手术治疗,但该病基本不能治愈。只有15%的胰腺癌患者可从外科手术中获益,而这些患者中仅有20%的生存时间能达到5年。胰腺癌手术治疗的并发症较多且常为致命性的,因此避免患者接受不必要的手术治疗显得至关重要。

尽管MRI-MRCP对于胰腺囊肿具有极高的诊断价值,但仅仅通过影像学手段难以对囊肿病变类型以及癌变可能性做出评估。

患者常把手术治疗视为胰腺癌治疗的“灵丹妙药”,但事实上大部分晚期胰腺癌患者甚至无法耐受手术过程。

胰腺囊肿和胰腺癌在美国人群中的发病率逐渐升高,具体原因尚不清楚,但已公认的危险因素包括肥胖、吸烟和胰腺癌家族史。

现如今美国胰腺囊肿的患病率为3%,尽管很多患者无临床症状或尚未确诊,大部分胰腺囊肿为癌前病变,但也有完全良性或恶性的病例。临床上需要通过对患者进行长期随访、创伤性活检检查,甚至是非必需的外科手术来明确胰腺囊肿的性质。研究人员称新型生化标记物VEGF-A的检测使患者无需接受长期随访,一些非典型良性囊肿患者可免于诊断性手术。

原始出处

Yip-Schneider MT1, Wu H2, Dumas RP2, Hancock BA2, Agaram N3, Radovich M2, Schmidt CM4.Vascular Endothelial Growth Factor, a Novel and Highly Accurate Pancreatic Fluid Biomarker for Serous Pancreatic Cysts.J Am Coll Surg. 2013 Dec 24.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=35136, encodeId=0182351363b, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:16:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904422, encodeId=f55b1904422b5, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Mon Oct 13 01:39:00 CST 2014, time=2014-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753055, encodeId=f1e51e5305599, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Aug 02 14:39:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279043, encodeId=beba12e904388, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Feb 21 04:39:00 CST 2014, time=2014-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340726, encodeId=08ce1340e2651, content=<a href='/topic/show?id=74a140404de' target=_blank style='color:#2F92EE;'>#囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40404, encryptionId=74a140404de, topicName=囊肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Fri Feb 21 04:39:00 CST 2014, time=2014-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604497, encodeId=1bb4160449ea1, content=<a href='/topic/show?id=6caf83951ab' target=_blank style='color:#2F92EE;'>#胰腺囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83951, encryptionId=6caf83951ab, topicName=胰腺囊肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8d19200231, createdName=wenzhiren, createdTime=Fri Feb 21 04:39:00 CST 2014, time=2014-02-21, status=1, ipAttribution=)]
    2015-08-06 hlycom3356

    期待有更多研究

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=35136, encodeId=0182351363b, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:16:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904422, encodeId=f55b1904422b5, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Mon Oct 13 01:39:00 CST 2014, time=2014-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753055, encodeId=f1e51e5305599, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Aug 02 14:39:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279043, encodeId=beba12e904388, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Feb 21 04:39:00 CST 2014, time=2014-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340726, encodeId=08ce1340e2651, content=<a href='/topic/show?id=74a140404de' target=_blank style='color:#2F92EE;'>#囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40404, encryptionId=74a140404de, topicName=囊肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Fri Feb 21 04:39:00 CST 2014, time=2014-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604497, encodeId=1bb4160449ea1, content=<a href='/topic/show?id=6caf83951ab' target=_blank style='color:#2F92EE;'>#胰腺囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83951, encryptionId=6caf83951ab, topicName=胰腺囊肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8d19200231, createdName=wenzhiren, createdTime=Fri Feb 21 04:39:00 CST 2014, time=2014-02-21, status=1, ipAttribution=)]
    2014-10-13 wjywjy
  3. [GetPortalCommentsPageByObjectIdResponse(id=35136, encodeId=0182351363b, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:16:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904422, encodeId=f55b1904422b5, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Mon Oct 13 01:39:00 CST 2014, time=2014-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753055, encodeId=f1e51e5305599, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Aug 02 14:39:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279043, encodeId=beba12e904388, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Feb 21 04:39:00 CST 2014, time=2014-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340726, encodeId=08ce1340e2651, content=<a href='/topic/show?id=74a140404de' target=_blank style='color:#2F92EE;'>#囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40404, encryptionId=74a140404de, topicName=囊肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Fri Feb 21 04:39:00 CST 2014, time=2014-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604497, encodeId=1bb4160449ea1, content=<a href='/topic/show?id=6caf83951ab' target=_blank style='color:#2F92EE;'>#胰腺囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83951, encryptionId=6caf83951ab, topicName=胰腺囊肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8d19200231, createdName=wenzhiren, createdTime=Fri Feb 21 04:39:00 CST 2014, time=2014-02-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=35136, encodeId=0182351363b, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:16:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904422, encodeId=f55b1904422b5, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Mon Oct 13 01:39:00 CST 2014, time=2014-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753055, encodeId=f1e51e5305599, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Aug 02 14:39:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279043, encodeId=beba12e904388, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Feb 21 04:39:00 CST 2014, time=2014-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340726, encodeId=08ce1340e2651, content=<a href='/topic/show?id=74a140404de' target=_blank style='color:#2F92EE;'>#囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40404, encryptionId=74a140404de, topicName=囊肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Fri Feb 21 04:39:00 CST 2014, time=2014-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604497, encodeId=1bb4160449ea1, content=<a href='/topic/show?id=6caf83951ab' target=_blank style='color:#2F92EE;'>#胰腺囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83951, encryptionId=6caf83951ab, topicName=胰腺囊肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8d19200231, createdName=wenzhiren, createdTime=Fri Feb 21 04:39:00 CST 2014, time=2014-02-21, status=1, ipAttribution=)]
    2014-02-21 yaanren
  5. [GetPortalCommentsPageByObjectIdResponse(id=35136, encodeId=0182351363b, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:16:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904422, encodeId=f55b1904422b5, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Mon Oct 13 01:39:00 CST 2014, time=2014-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753055, encodeId=f1e51e5305599, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Aug 02 14:39:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279043, encodeId=beba12e904388, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Feb 21 04:39:00 CST 2014, time=2014-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340726, encodeId=08ce1340e2651, content=<a href='/topic/show?id=74a140404de' target=_blank style='color:#2F92EE;'>#囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40404, encryptionId=74a140404de, topicName=囊肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Fri Feb 21 04:39:00 CST 2014, time=2014-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604497, encodeId=1bb4160449ea1, content=<a href='/topic/show?id=6caf83951ab' target=_blank style='color:#2F92EE;'>#胰腺囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83951, encryptionId=6caf83951ab, topicName=胰腺囊肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8d19200231, createdName=wenzhiren, createdTime=Fri Feb 21 04:39:00 CST 2014, time=2014-02-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=35136, encodeId=0182351363b, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:16:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904422, encodeId=f55b1904422b5, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Mon Oct 13 01:39:00 CST 2014, time=2014-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753055, encodeId=f1e51e5305599, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Aug 02 14:39:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279043, encodeId=beba12e904388, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Feb 21 04:39:00 CST 2014, time=2014-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340726, encodeId=08ce1340e2651, content=<a href='/topic/show?id=74a140404de' target=_blank style='color:#2F92EE;'>#囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40404, encryptionId=74a140404de, topicName=囊肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Fri Feb 21 04:39:00 CST 2014, time=2014-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604497, encodeId=1bb4160449ea1, content=<a href='/topic/show?id=6caf83951ab' target=_blank style='color:#2F92EE;'>#胰腺囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83951, encryptionId=6caf83951ab, topicName=胰腺囊肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8d19200231, createdName=wenzhiren, createdTime=Fri Feb 21 04:39:00 CST 2014, time=2014-02-21, status=1, ipAttribution=)]

相关资讯

Cancer Res:非靶组织代谢组学发现肝癌的新型血清标志物

  第二军医大学东方肝胆外科医院王红阳院士、中科院大连化学物理研究所许国旺研究员领衔的项目组通过对肝组织进行代谢谱分析,了解了肝癌的代谢特征,并揭示了两个有潜力作为癌症生物标记物,用于肝癌临床诊断的代谢产物。专家认为,该研究对于开发更有效的治疗策略,改善疾病结局,降低肝癌发病率及死亡率具有重要意义。其研究论文日前发表在《癌症研究》杂志上。   代谢异常被视为肿瘤的一个重要特征,解析癌症代

Int J Cancer:口腔癌新型生物标记物或加速个体化疗法开发

近日,来自多伦多大学的研究者通过研究鉴别出了一种特殊的蛋白质,其可以帮助医生预测是否个体会患口腔癌,相关研究刊登于国际杂志International Journal of Cancer上。 口腔癌是亚洲常见的癌症之一,研究者发现这种新型蛋白质可以扮演生物标志物的角色,从而帮助研究者确定患者口腔的损坏程度是否会导致口腔癌的发生。某些癌症发病快而且损害程度大,但是有些癌症却发病缓慢,而且容易

呼气测肺癌 可与X光相媲美?

 有朝一日,呼气测试将不仅仅能测出你是否醉酒。最近,位于加州山景城(Mountain View, California)的Metabolomx新创公司完成了一项临床测试,显示公司研发的呼气测试能够检测出肺癌,准确率达83%,而且还能区别几种不同类型的肺癌,而通常这种区分测试都需要活组织切片检查。该检测的准确率可以和小剂量肺部X光成像相媲美。 呼气测试器内部:被测试人呼出的气体通过排成数

CURR OPIN NEPHROL HY:生物标记物可更好地预测慢性肾病患者结局

  加拿大温哥华英属哥伦比亚大学医学院肾内科的De Serres SA等人认为,更好地预测慢性肾病患者的结局一直是一个重要目标。日益复杂的生物标记物可更好地研究临床目标,提高治疗干预的性质和时间,并引导资源的配置。该研究结果在线发表于2012年11月份的CURR OPIN NEPHROL HY杂志上。     不管是对于病人还是对医疗系统来说,预测慢性肾病患者的结局都是一件相当重要的